Revenue (Tables)

3 Months Ended

Mar. 31, 2022

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

The following table summarizes the disaggregation of revenue by nature:

	Three Months Ended March 31,
Dollars in Millions	2022		2021
Net product sales	$	11,308	$	10,798
Alliance revenues	188		142
Other revenues	152		133
Total Revenues	$	11,648	$	11,073

Revenue Recognition Gross-To-Net Adjustments

The following table summarizes GTN adjustments:

	Three Months Ended March 31,
Dollars in Millions	2022		2021
Gross product sales	$	16,650	$	15,559
GTN adjustments(a)
Charge-backs and cash discounts	(1,763)		(1,586)
Medicaid and Medicare rebates	(2,084)		(1,718)
Other rebates, returns, discounts and adjustments	(1,495)		(1,457)
Total GTN adjustments	(5,342)		(4,761)
Net product sales	$	11,308	$	10,798

(a)    Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $74 million and $217 million for the three months ended March 31, 2022, and 2021, respectively.

Revenue from External Customers by Products and Services

The following table summarizes the disaggregation of revenue by product and region:

	Three Months Ended March 31,
Dollars in Millions	2022		2021
In-Line Products
Eliquis	$	3,211	$	2,886
Opdivo	1,923		1,720
Pomalyst/Imnovid	826		773
Orencia	792		758
Sprycel	483		470
Yervoy	515		456
Empliciti	75		85
Mature and other products	462		506
New Product Portfolio
Reblozyl	156		112
Abecma	67		—
Zeposia	36		18
Breyanzi	44		—
Inrebic	18		16
Onureg	23		15
Opdualag	6		—
Recent LOE Products(a)
Revlimid	2,797		2,944
Abraxane	214		314
Total Revenues	$	11,648	$	11,073
United States	$	7,694	$	7,010
Europe	2,413		2,553
Rest of the World	1,314		1,346
Other(b)	227		164
Total Revenues	$	11,648	$	11,073

(a)    Recent LOE Products includes products with significant decline in revenue from the prior reporting period as a result of a loss of exclusivity.

(b)    Other revenues include royalties and alliance-related revenues for products not sold by BMS’s regional commercial organizations.